Semaglutide is effective in type 2 diabetes and obesity with schizophrenia

被引：0
|
作者：
Kaoru Noda
Takehiro Kato
Nao Nomura
Mayu Sakai
Sodai Kubota
Tokuyuki Hirose
Yanyan Liu
Yoshihiro Takahashi
Ken Takao
Masami Mizuno
Takuo Hirota
Tetsuya Suwa
Yukio Horikawa
Daisuke Yabe
机构：
[1] Gifu University Graduate School of Medicine,Department of Diabetes, Endocrinology and Metabolism
[2] Gifu University Graduate School of Medicine,Department of Rheumatology and Clinical Immunology
[3] Kansai Electric Power Medical Research Institute,Yutaka Seino Distinguished Center for Diabetes Research
[4] Tokai National Higher Education and Research System,Center for Healthcare Information Technology
[5] Kobe University Graduate School of Medicine,Division of Molecular and Metabolic Medicine
来源：
Diabetology International | 2022年 / 13卷
关键词：
GLP-1 receptor agonist; Schizophrenia; Obesity; Type 2 diabetes; Bodyweight;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：693 / 697
页数：4
相关论文
共 50 条
  • [31] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Williams, Thomas C.
    Stewart, Emma
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 891 - 891
  • [32] ORAL SEMAGLUTIDE: THE INNOVATION IN TYPE 2 DIABETES MANAGEMENT
    Shestakova, Marina V.
    Shamkhalova, Minara Sh.
    Galstyan, Gagik R.
    Ruyatkina, Ludmila A.
    Suplotova, Ludmila A.
    DIABETES MELLITUS, 2021, 24 (03): : 273 - 281
  • [33] Effects of Semaglutide on CKD in Patients With Type 2 Diabetes
    Kotwal, Sradha S.
    Perkovic, Vlado
    KIDNEY INTERNATIONAL REPORTS, 2025, 10 (02): : 287 - 290
  • [34] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Marso, Steven P.
    Bain, Stephen C.
    Consoli, Agostino
    Eliaschewitz, Freddy G.
    Jodar, Esteban
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Rosenstock, Julio
    Seufert, Jochen
    Warren, Mark L.
    Woo, Vincent
    Hansen, Oluf
    Holst, Anders G.
    Pettersson, Jonas
    Vilsboll, Tina
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1834 - 1844
  • [35] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Zweck, Elric
    Westenfeld, Ralf
    Szendroedi, Julia
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2075 - 2076
  • [36] Obesity: Effective and Safe Weight Loss with Semaglutide?
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2018, 56 (12): : 1466 - 1466
  • [37] Semaglutide and cardiovascular outcomes in obesity without diabetes
    Basolo, A.
    Fierabracci, P.
    Salvetti, G.
    Santini, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (05) : 1047 - 1049
  • [38] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
    Lincoff, A. Michael
    Brown-Frandsen, Kirstine
    Colhoun, Helen M.
    Deanfield, John
    Emerson, Scott S.
    Esbjerg, Sille
    Hardt-Lindberg, Soren
    Hovingh, G. Kees
    Kahn, Steven E.
    Kushner, Robert F.
    Lingvay, Ildiko
    Oral, Tugce K.
    Michelsen, Marie M.
    Plutzky, Jorge
    Tornoe, Christoffer W.
    Ryan, Donna H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (24): : 2221 - 2232
  • [39] Single-center experience in using a once weekly Semaglutide injection in adolescents with obesity +/- Type 2 diabetes
    Dauleh, Hajar
    Amin, Rasha
    Pasha, Maheen
    Gad, Hoda
    Elshareif, Tamara
    Khalifa, Amel
    Petrovski, Goran
    Ahmed, Elwaseila
    Mohamadsalih, Ghassan
    Chirayath, Shiga
    Albureshad, Khalid
    Ibrahim, Marwa
    Campbell, Judith
    Hamdan, Manar
    Almajaly, Douha
    Umer, Fareeda
    Albahri, Aya
    Isamil, Fatima
    Saeed, Sara
    Almasarweh, Hadeel
    Cuatrona, Erlinda
    Biglangawa, Roshirl
    Inso, Gina
    Aler, Joanna
    Eyalawwad, Ayah A.
    Malik, Rayaz
    Hussain, Khalid
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 377 - 378
  • [40] Obesity and type 2 diabetes
    Maggio, CA
    Pi-Sunyer, FX
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2003, 32 (04) : 805 - +
12345